Bibliographies thématiques / FK-506 (Drug)

Sommaire

  1. Articles de revues
  2. Thèses
  3. Livres
  4. Chapitres de livres

Littérature scientifique sur le sujet « FK-506 (Drug) »

Auteur : Grafiati
Publié le 4 juin 2021
Mis à jour le 19 février 2022

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « FK-506 (Drug) ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "FK-506 (Drug)"

1

Shaw, L. M., and K. L. Brayman. "FK-506 therapeutic drug monitoring." Clinical Chemistry 40, no. 12 (December 1, 1994): 2207–8. http://dx.doi.org/10.1093/clinchem/40.12.2207.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Winkler, M., B. Ringe, J. Baumann, M. Loss, K. Wonigeit, and R. Pichlmayr. "Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression." Clinical Chemistry 40, no. 12 (December 1, 1994): 2247–53. http://dx.doi.org/10.1093/clinchem/40.12.2247.

Texte intégral
Résumé :
Abstract By retrospective analysis of 13,000 blood samples obtained from 248 patients receiving FK 506 therapy, we compared the suitability of plasma with that of whole blood as the matrix for therapeutic drug monitoring of FK 506. The plasma concentrations did not correlate with the concentrations in whole blood (r = 0.56). In contrast to plasma samples (analyzed by enzyme immunoassay), FK 506 was detectable in all whole-blood samples (analyzed by enzyme immunoassay/microparticle enzyme immunoassay). The inter- and intraindividual variations of FK 506 measurements were greater in plasma than
Styles APA, Harvard, Vancouver, ISO, etc.
3

Dumont, F. J., M. J. Staruch, S. L. Koprak, J. J. Siekierka, C. S. Lin, R. Harrison, T. Sewell, V. M. Kindt, T. R. Beattie, and M. Wyvratt. "The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin." Journal of Experimental Medicine 176, no. 3 (September 1, 1992): 751–60. http://dx.doi.org/10.1084/jem.176.3.751.

Texte intégral
Résumé :
FK-506 inhibits Ca(2+)-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis-trans peptidyl-prolyl isomerase activity (PPIase) activity. Because rapamycin (RAP) sim
Styles APA, Harvard, Vancouver, ISO, etc.
4

Rokaw, M. D., M. E. West, P. M. Palevsky, and J. P. Johnson. "FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells." American Journal of Physiology-Cell Physiology 271, no. 1 (July 1, 1996): C194—C202. http://dx.doi.org/10.1152/ajpcell.1996.271.1.c194.

Texte intégral
Résumé :
The immunosuppressants cyclosporin A (CyA), FK-506, and rapamycin (RAP) have multiple actions on target cells that appear to be mediated by interaction of drug-binding protein complexes. Both FK-506 and CyA, but not RAP, inhibit the Ca2(+)-dependent phosphatase, calcineurin, and in so doing have been found to inhibit Na(+)-K(+)-ATPase activity in various nephron segments. Of interest, FK-506 and RAP, but not CyA, are bound by the steroid receptor-associated FK-506-binding heat shock protein of 56 kDa, HSP56. To determine the physiological effect of this interaction on a steroid-mediated phenom
Styles APA, Harvard, Vancouver, ISO, etc.
5

Di Padova, F. E. "Pharmacology of CsA and FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 49–56. http://dx.doi.org/10.1007/bf02171736.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Goulet, Mark T., Kathleen M. Rupprecht, Peter J. Sinclair, Matthew J. Wyvratt, and William H. Parsons. "The medicinal chemistry of FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 145–62. http://dx.doi.org/10.1007/bf02171741.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Petros, Andrew M., Gerd Gemmecker, Placido Neri, Edward T. Olejniczak, David Nettesheim, Robert X. Xu, Earl G. Gubbins, Harriet Smith, and Stephen W. Fesik. "NMR studies of an FK-506 analog, [U-carbon-13]ascomycin, bound to FK-506-binding protein." Journal of Medicinal Chemistry 35, no. 13 (June 1992): 2467–73. http://dx.doi.org/10.1021/jm00091a015.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Kay, John E., Senam E. A. Doe, and C. Robin Benzie. "The mechanism of action of the immunosuppressive drug FK-506." Cellular Immunology 124, no. 1 (November 1989): 175–81. http://dx.doi.org/10.1016/0008-8749(89)90121-4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

O'connor, Stephen P., Robert L. Ellsworth, Mary Nallin Omstead, Rosalind G. Jenkins, and Louis Kaplan. "The preparation of 14C-labeled FK-506." Journal of Labelled Compounds and Radiopharmaceuticals 31, no. 2 (February 1992): 103–8. http://dx.doi.org/10.1002/jlcr.2580310205.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Jusko, William J. "Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 17, no. 6 (December 1995): 596–601. http://dx.doi.org/10.1097/00007691-199512000-00009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "FK-506 (Drug)"

1

Karlsson, Håkan. "Influence of FK506 on certain aspects of lymphocyte activation and lymphocyte-endothelial cell interactions in vitro." Lund : Dept. of Medical Microbiology, Section of Clinical Immunology, Lund University, 1997. http://catalog.hathitrust.org/api/volumes/oclc/39799195.html.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Whitaker, Audie D. "The role of interferon-gamma in cyclosporine A or FK-506 treated L. major infected mice." Virtual Press, 1999. http://liblink.bsu.edu/uhtbin/catkey/1138295.

Texte intégral
Résumé :
Certain strains of mice, e.g. C57BL/6, are highly resistant to serious infections with the protozoan pathogen, Leishmania major, whereas other strains, e.g. BALB/c, are not. It has beenproposed that interferon gamma (IFN-y) is one of the most critical lymphokines produced in a protective response to these intracellular pathogens. IFN-y has been classified as a Thi lymphokine produced by the Thl subset of T lymphocytes which not only activates macrophages to kill the protozoa but also helps regulates the immune system overall to form a lasting immunity to the microorganism (4,19). Mice suscepti
Styles APA, Harvard, Vancouver, ISO, etc.
3

Potter, Shannon M. "The role of cyclosporin A, leptin, and FK-506 in Leishmania major infections in mice." Muncie, Ind. : Ball State University, 2009. http://cardinalscholar.bsu.edu/467.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Jones, Terence Edward. "Economically beneficial drug interactions with cyclosporin and tacroliumus : clinical studies in recipients of kidney and liver transplants." Title page, contents and abstract only, 2000. http://web4.library.adelaide.edu.au/theses/09PH/09phj79.pdf.

Texte intégral
Résumé :
Bibliography: leaves 234-257. Three separate clinical studies in organ transplant recipients are presented. The aims are to examine fundamental questions regarding the clinically and economically important pharmokinetic interaction between diltiazem and cyclosporin, an interaction widely utilised in organ transplantation. The data contained should assist the development of soundly based policies that will ensure a benefit exists before a sparing agent is coprescribed, and that the lowest effective dose of sparing agent is used.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Soubhia, Rosa Maria Cordeiro. "Avaliação dos efeitos nefrotóxicos da associação do tacrolimus (FK 506) e antiinflamatórios não-hormonais em ratos." Faculdade de Medicina de São José do Rio Preto, 2005. http://bdtd.famerp.br/handle/tede/166.

Texte intégral
Résumé :
Made available in DSpace on 2016-01-26T12:51:42Z (GMT). No. of bitstreams: 1 rosasoubhia_tese.pdf: 792706 bytes, checksum: bba71696e22270729d09c3130cc047eb (MD5) Previous issue date: 2005-05-25<br>Introduction: Tacrolimus (FK 506) is a potent immunosuppressive drug that may cause nephrotoxicity decreasing the renal blood flow (RBF) and glomerular filtration rate (GFR). Conventional non-steroidal anti-inflammatory drugs (NSAIDs) may cause nephrotoxicity, interfering with renal hemodynamics and fluid and eletrolyte homeostasis. Recently, new selective COX-2 inhibitors have been developed produ
Styles APA, Harvard, Vancouver, ISO, etc.
6

Toske, Steven Gerald. "Part I : synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506." Thesis, 1993. http://hdl.handle.net/1957/35676.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Sinswat, Prapasri 1972. "Enhancing the delivery of poorly water soluble drugs using particle engineering technologies." 2006. http://hdl.handle.net/2152/13124.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Overhoff, Kirk Alan. "Improved oral bioavailability of poorly water soluble drugs using rapid freezing processes." 2006. http://hdl.handle.net/2152/13125.

Texte intégral
Résumé :
A growing number of therapeutic compounds currently being developed by pharmaceutical companies are poorly water soluble leading to limited and/or erratic bioavailability. The rate limiting step for absorption of these compounds is dependent on the dissolution and apparent solubility. Nanoparticle formation has been exploited as a method to improve the bioavailability of these poorly water soluble active pharmaceutical ingredients (API) by increasing the dissolution rates and apparent solubilities. The influence of hydrophilic stabilizers in powder compositions prepared by the spray freezing i
Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "FK-506 (Drug)"

1

FK506 and organ transplantation. Austin: R.G. Landes, 1994.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Raptis, Dimitrios, and Manousos-Georgios Pramateftakis. Tacrolimus: Effectiveness, Safety and Drug Interactions. Nova Science Publishers, Incorporated, 2013.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Tacrolimus in organ transplantation: Prevention and treatment of allograft rejections. Lengerich: Pabst Science Publishers, 1998.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Toske, Steven Gerald. Part I: Synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506. 1993.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Thomas, Ruzicka, and Reitamo Sakari, eds. Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2004.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

(Editor), T. Ruzicka, and S. Reitamo (Editor), eds. Tacrolimus. Springer, 2003.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2003.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "FK-506 (Drug)"

1

Rossaro, L., S. R. Dowd, V. Simplaceanu, R. Naccarato, D. H. Van Thiel, and C. Ho. "Effect of FK 506 and Cyclosporins on Model Membranes Studied by Nuclear Magnetic Resonance Spectroscopy." In Drugs and the Liver: High Risk Patients and Transplantation, 177–84. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1994-8_29.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

"Tacrolimus (FK-506)." In Drug Therapy in Dermatology, 172–81. CRC Press, 2000. http://dx.doi.org/10.1201/b14006-12.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

KOCIENSKI, PHILIP, MICHAEL STOCKS, and DAVID K. DONALD. "Recent Progress in Research on the Immunosuppressant FK-506." In Chirality in Drug Design and Synthesis, 131–65. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-12-136670-4.50014-x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « FK-506 (Drug) » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie